*If RASs at baseline Harvoni x 12 wks 95% (83/87; ION-2) Zepatier + RBV x 12 wks Mavyret x 12 wks 92% (23/25; MAGELLAN-1)

Similar documents
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos

Hepatitis C in Special Populations

Saeed Hamid, MD Alex Thompson, MD, PhD

Update on chronic hepatitis C treatment: current trends, new challenges, what next?

Current HCV Treatment by Genotype

Genotype 1 Treatment Naïve No Cirrhosis Options

Viva La Revolución: Options to Combat Hepatitis C

Current HCV Treatment by Genotype Ira M. Jacobson, MD

Expert Perspectives: Best of HCV from EASL 2015

Treatment of Unique Populations Raymond T. Chung, MD

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients

Treating HCV After Liver Transplantation: What are the Treatment Options?

HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland

HCV Management in Decompensated Cirrhosis: Current Therapies

Updates on the AASLD/IDSA HCV Guidance

Treatments of Genotype 2, 3,and 4: Now and in the future

10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives

Management of Chronic HCV 2017 and Beyond

TREATMENT OF GENOTYPE 2

10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection

HCV In 2015: Maximizing SVR

HCV Update from AASLD 2016

Case. 63 year old woman now with:

Disclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH

Glecaprevir and Pibrentasvir in HCV GT 1-6 without Cirrhosis SURVEYOR-I and SURVEYOR-II

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

Treating now vs. post transplant

VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015

Baseline and acquired viral resistance to DAAs: how to test and manage

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

A treatment revolution: current management for chronic HCV

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018

HCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016

Selecting HCV Treatment

Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV

5/10/2016. Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients. HCV life-cycle and antiviral targets

Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York

Case 2: A 71-year-old man with cirrhosis

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France

Antiviral treatment in Unique Populations

Tough Cases in HIV/HCV Coinfection

HCV Disease Outcomes in the US. Hepatitis C New Medications, New Hope and New Opportunities for Primary Care. Learning Objectives 10/13/17

Management of HCV in Prior Treatment Failure

Hepatitis C Update: Screening, Diagnosis, and Treatment

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London

HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI

HCV Treatment of Genotype 1: Now and in the Future

Update in the Management of Hepatitis C: What Does the Future Hold

Length of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

New Hepatitis C Antivirals

HCV-G3: Sofosbuvir with ledipasvir or daclatasvir?

SOLAR-1 (Cohorts A and B)

Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD

Potential Issues in Treating HIV/HCV co-infection with new HCV antivirals

HCV therapy : Clinical case

HCV Treatment in 2016

What do we need to know about RAVs clinically?

Drug Class Prior Authorization Criteria Hepatitis C

HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD

Treatment of HCV in 2016

Clinical Criteria for Hepatitis C (HCV) Therapy

Outline. HCV Disease Outcomes in the US. Hepatitis C: The New Landscape 5/24/16. Advances in Internal Medicine May 24, I have no disclosures

Management of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World

Latest Treatment Updates for GT 2 and GT 3 Patients

Need to Assess HCV Resistance to DAAs: Is it Useful and When?

Management of HCV Tawesak Tanwandee

Why make this statement?

HEPATITIS C: UPDATE AND MANAGEMENT

Hepatitis C: The New World of Treatment

Learning Objective. After completing this educational activity, participants should be able to:

HCV treatment options in clinical practice. Current treatment options for HCV-G4

Hepatitis C Direct-Acting Antivirals

6/2/2015. Interactive Case-Based Presentations and Audience Discussion

New Exception Status Benefits

Hepatitis C Genotypes

DAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4

Disclosures. Outline Update on HCV management & treatment in Primary care. What role does the Family Practice Provider play in HCV care in 2014?

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Ledipasvir-Sofosbuvir (Harvoni)

Update on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017

4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives

Treatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )

Clinical Criteria for Hepatitis C (HCV) Therapy

Hepatitis C Difficult to Treat. Population. Disclosures

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015

Transcription:

PATIENTS WITHOUT CIRRHOSIS GENOTYPE Naïve Harvoni x 8 wks (if HCV 97% (119/123; ION-3), 97% - HCV- Epclusa x 12 wks 98% (206/210; ASTRAL-1), RNA <6mill, F0-F2, No HIV) TARGET 99% (170/172; 1a Mavyret x 8 wks 99% (348/351; ENDURANCE-1) Harvoni x 12 wks 95%, Naive (179/180; ION-1, 206/216; ION-3) Zepatier x 12 wks 99% (133/135, C-EDGE TN) *if no RASs at baseline Peg/RBV experienced Epclusa x 12 wks 98% (206/210; ASTRAL-1), 99% Zepatier + RBV x 16 wks 97% (C-EDGE TE) (170/172; *if RASs at baseline Harvoni x 12 wks 95%, Exp (83/87; ION-2) Zepatier x 12 wks 99% (390/393, pooled data) Mavyret x 8 wks 99% (348/351; ENDURANCE-1) *if No RASs at baseline 1b Peg/RBV/PI experienced Epclusa x 12 wks 98% (206/210; ASTRAL-1) Zepatier + RBV x 16 wks *If RASs at baseline Harvoni x 12 wks 95% (83/87; ION-2) Zepatier + RBV x 12 wks 92% (23/25; MAGELLAN-1) *If No RASs at baseline SOF-experienced (no 97% (C-EDGE TE) 96% (C-SALVAGE) 99% (348/351; ENDURANCE-1) Epclusa + RBV x 12 wks 89% (39/44; POLARIS-4, w/o Vosevi x 12 wks 97% (35/36; POLARIS-4) RBV) NS5A-experienced Vosevi x 12 wks 97% (66/68; POLARIS-1) Mavyret x 16 wks (PI-naïve) 94% (16/17; MAGELLAN-1) Naïve Harvoni x 8 wks (if HCV RNA <6mill, F0-F2, No HIV) 97% (119/123; ION-3)97% - HCV-TARGET Epclusa x 12 wks 99% (117/118; ASTRAL-1), 97% (57/59); Mavyret x 8 wks 99% (348/351; ENDURANCE-1) Harvoni x 12 wks 95% (179/180; ION-1, 206/216; ION-3) Peg/RBV experienced Epclusa x 12 wks 99% (117/118; ASTRAL-1), 97% (57/59); Harvoni x 12 wks Mavyret x 8 wks Zepatier x 12 wks 95% (179/180; ION-1, 206/216; ION-3) 99% (348/351; ENDURANCE-1) 100%, (35/35,C-EDGE TE) Zepatier x 12 wks 98%, (129/131,C-EDGE) Peg/RBV/PI Experienced Epclusa x 12 wks 99% (117/118; ASTRAL-1) Zepatier + RBV x 12 wks 96% (C-SALVAGE) SOF-experienced (no Harvoni x 12 wks 95% (83/87; ION-2) 92% (23/25; MAGELLAN-1) 99% (348/351; ENDURANCE-1) Epclusa + RBV x 12 wks 95% (21/22; POLARIS-4, no RBV) NS5A-experienced Vosevi x 12 wks 100% (29/29; POLARIS-1) Mavyret x 16 wks (PI-naïve) 94% (16/17; MAGELLAN-1)

Genotype 2 3 4 5/6 Experienced (no prior SOF) Epclusa x 12 wks 100% (104/104; ASTRAL-1), 99% (133/134; ASTRAL-2), 100% (53/53; Mavyret x 8 wks 98% (193/197; SURVEYOR-2) SOF + DCV x 12 wks 100% (13/13), Ally-2, HIV/HCV SOF-Experienced 98% (193/197; SURVEYOR-2) Epclusa x 12 wks 97% (32/33; POLARIS-4) NS5A-experienced Vosevi x 12 wks 100% (5/5; POLARIS-1) Naïve Epclusa x 12 wks 98% (160/163; ASTRAL-3), 97% (86/89; prior SOF) SOF-experienced (no Mavyret x 8 wks 95% (149/157; ENDURANCE-3) Epclusa x 12 wks 94% (31/33; ASTRAL-3), 97% (86/89; Mavyret x 16 wks 95% (21/22; SURVEYOR-2) SOF + DCV x 12 wks 97% (73/75, ALLY-3) Mavyret x 16 wks 95% (21/22; SURVEYOR-2) Epclusa + RBV x 12 wks 85% (44/52; POLARIS-4, w/o Vosevi x 12 wks 96% (52/54; POLARIS-4) RBV) NS5A-experienced Vosevi x 12 wks 100% (22/22; POLARIS-1) Naïve Epclusa x 12 wks 100% (116/116; ASTRAL-1), 98% (56/57; Harvoni x 12 wks 93% (41/44, Study 1119, w/wo cirrhosis) P/R or SOF-Experienced (no prior NS5A or PI) Mavyret x 8 wks 93% (43/46; SURVEYOR-2, Part 4) Zepatier x 12 wks 97% (64/66, C-SCAPE, C-EDGE TN, C-EDGE CO INFXN, incl some cirrhotics) Epclusa x 12 wks 100% (116/116; ASTRAL-1), 98% (56/57; Harvoni x 12 wks 93% (41/44, Study 1119) Mavyret x 8 wks 93% (43/46; SURVEYOR-2, Part 4) Zepatier + RBV x 16 wks NS5A-experienced Vosevi x 12 wks 91% (20/22; POLARIS-1) P/R or SOF- prior NS5A or PI) Epclusa x 12 wks GT5: 97% (34/35; ASTRAL-1) GT6: 100% (41/41; ASTRAL-1, 9/9; Harvoni x 12 wks GT5: 93% (38/41) GT6: 96% (24/25; ELECTRON-2) NS5A-experienced Vosevi x 12 wks GT5: 100% (1/1; POLARIS-1) GT6: 100% (6/6; POLARIS-1) Mavyret x 8 wks 100% (8/8, C-EGDE TE) GT5: 100% (2/2; SURVEYOR-2, Part 4) GT6: 100% (10/10; SURVEYOR- 2, Part 4)

PATIENTS WITH COMPENSATED CIRRHOSIS 1a, (CP-A) GENOTYPE 1A Naïve Epclusa x 12 wks 100% (31/31; ASTRAL-1, all GT1 TN/Cirrhosis), 99% (170/172, POLARIS- 2, incl non-cirrhotic) Harvoni x 12 wks *add RBV if RAV at 28, 30, 31 or 93 99% (89/90, EXPEDITION-1) Zepatier x 12 wks *If No RASs at baseline Zepatier + RBV x 16 wks *If RASs at baseline 94% (32/35: ION-1), 96% 95% (C-EDGE TN) 97% (C-EDGE TE) Peg/RBV experienced Peg/RBV/PI experienced (no Epclusa x 12 wks 98% (41/42; ASTRAL-1, all GT1 TE/Cirrhosis, no RBV), 99% (170/172, POLARIS-2, incl non-cirrhotic) 99% (89/90, EXPEDITION-1) Zepatier x 12 wks *If No RASs at baseline Zepatier + RBV x 16 wks *If RASs at baseline Epclusa x 12 wks 98% (41/42; ASTRAL-1, all GT1 TE/Cirrhosis, no RBV) Harvoni x + RBV x 12 wks 96% (74/77; SIRIUS), 96% 94% (C-EDGE, TE) 97% (C-EDGE TE) Harvoni x + RBV x 12 wks 96% (74/77; SIRIUS), 96% Zepatier + RBV x 12 wks *If No RASs at baseline 92% (23/25; MAGELLAN-1) Zepatier + RBV x 16 wks *If RASs at baseline 96% (76/79, C-SALVAGE) 97% (C-EDGE TE) Prior SOF (no prior NS5A) 99% (89/90, EXPEDITION-1) Vosevi x 12 wks 97% (35/36; POLARIS-4, incl noncirrhotic) NS5A-experienced Vosevi x 12 wks 94% (31/33; POLARIS-1) Mavyret x 16 wks (PI-naïve) 94% (16/17; MAGELLAN-1)

GENOTYPE 1B 1b, (CP-A) Naïve Epclusa x 12 wks 100% (31/31; ASTRAL-1, all GT1 TN/Cirrhosis), 97% (57/59; Harvoni x 12 wks 94% (32/35: ION-1), 96% 99% (89/90, EXPEDITION-1) Zepatier x 12 wks 95% (C-EDGE TN) Peg/RBV failure Epclusa x 12 wks 98% (41/42; ASTRAL-1, all GT1 TE/Cirrhosis, no RBV), 97% (57/59; Harvoni + RBV x 12 wks 96% (74/77; SIRIUS), 96% 99% (89/90, EXPEDITION-1) Zepatier x 12 wks Peg/RBV/PI failure Epclusa x 12 wks 94% (C-EDGE TE) 98% (41/42; ASTRAL-1, all GT1 TE/Cirrhosis, no RBV) Harvoni x + RBV x 12 wks 96% (74/77; SIRIUS), 96% Zepatier + RBV x 12 wks 96% (76/79, C-SALVAGE) 92% (23/25; MAGELLAN-1) Peg/RBV/SOF or SOF/RBV failure (excludes NS5A failure) Epclusa + RBV x 12 wks 95% (21/22; POLARIS-4, incl noncirrhotics, no RBV) 99% (89/90, EXPEDITION-1) NS5A-experienced Vosevi x 12 wks 100% (16/16; POLARIS-1) Mavyret x 16 wks (PI-naïve) 94% (16/17; MAGELLAN-1)

(CP A) prior SOF) GENOTYPE 2 Epclusa x 12 wks 100% (29/29; ASTRAL-1, ASTRAL-2, TN/TE) 100% (31/31; EXPEDITION-1) SOF/RBV failure 100% (31/31; EXPEDITION-1) Epclusa + RBV x 12 wks 97% (32/33: POLARIS-4, incl non-cirrhotics, no RBV) NS5A-experienced Vosevi x 12 wks 100% (5/5; POLARIS-1, all were noncirrhotic) (CP A) Naive GENOTYPE 3 Epclusa 12 wks *if Y93+ add RBV 93% (40/43; ASTRAL-3, no RBV), 99% (76/77; POLARIS-3) 98% (39/40, SURVEYOR-2 Part 3) prior SOF exposure) SOF Experienced (no prior NS5A exposure) Mavyret x 16 wks 98% (39/40, SURVEYOR-2 Part 3) Epclusa +RBV x 12 wks 89% (33/37; ASTRAL-3, no RBV), 91% (29/32; POLARIS- 3, w/o RBV) Vosevi x 12 wks 98% (106/110, POLARIS-3, 8wk duration, incl some TN and noncirrhotics) Mavyret x 16 wks 98% (39/40, SURVEYOR-2 Part 3) Epclusa +RBV x 12 wks *If Y93+ consider extension Vosevi x 12 wks 96% (52/54; POLARIS-4) to 24 weeks 85% (44/52; POLARIS-4, w/o RBV) NS5A-experienced Vosevi x 12 wks *if Y93+ add RBV 93% (52/56; POLARIS-1)

(CP A) GENOTYPE 4 Naïve Epclusa x 12 wks 100% (27/27; ASTRAL-1), 98% (56/57; POLARIS-2, incl non-cirrhotics) 100% (16/16; EXPEDITION-1) Harvoni x + RBV x 12 wks 93% (41/44, Study 1119, Zepatier x 12 wks 97% (64/66, C-SCAPE, C-EDGE) w/wo cirrhosis, no ribavirin). Peg/RBV experienced Epclusa x 12 wks 100% (27/27; ASTRAL-1, no RBV), 98% (56/57; POLARIS-2, incl non-cirrhotics, no RBV) Harvoni x + RBV x 12 wks 93% (41/44, Study 1119, w/wo cirrhosis, no ribavirin). Zepatier + RBV x 16 wks 100% (8/8, C-EDGE TE) NS5A-experienced Vosevi x 12 wks 85% (12/14; POLARIS-1) (CP A) Experienced (No GENOTYPE 5 and 6 Epclusa x 12 weeks GT5: 100% (5/5, ASTRAL-1) GT6: 100% (6/6, ASTRAL-1) GT5: 100% (2/2; EXPEDITION-1) Harvoni x 12 wks GT6: 96% (24/25; ELECTRON- 2. Two TE pts and two w/ cirrhosis, no RBV) GT6: 100% (7/7; EXPEDITION-1) NS5A-experienced Vosevi x 12 wks GT5: 100% (1/1; POLARIS-1, all noncirrhotic) GT6: 100% (6/6; POLARIS-1, all noncirrhotic) *NS5A RASs significant for Zepatier at positions 28, 30, 31 or 93.

prior SOF exposure) Experienced, SOF failure (excludes NS5A failure) PATIENTS WITH DECOMPENSATED CIRRHOSIS GENOTYPE 1a or 1b Epclusa + RBV x 12 wks Harvoni x + RBV x 12 wks 1a: 94% (51/54; ASTRAL-4) 1b: 100% (14/14; ASTRAL-4) CTP B x 12wks: 87% (45/52; SOLAR-1) CTP C x 12 wks: 88% (35/40; SOLAR-1) Epclusa x 24 wks (if unable to take RBV) Harvoni x 24 wks (if unable to take RBV) Epclusa + RBV x 24 wks No Data Harvoni + RBV x 24 wks No Data GENOTYPE 2 1a: 93% (51/55; ASTRAL-4) 1b: 88% (14/16; ASTRAL-4) No Data w/o RBV CTP B x 24 wks (w/rbv): 92% (48/52; SOLAR-1) CTP C x 24 wks (w/rbv): 82% (38/46; SOLAR-1) Epclusa + RBV x 12 wks 100% (4/4; ASTRAL-4) SOF + DCV + RBV x 12-24 wks 12 wks with RBV, Ally-1: CP-B 100% (2/2) CP-C 50% (1/2) GENOTYPE 3 Epclusa + RBV x 12 wks 85% (11/13; ASTRAL-4) SOF + DCV + RBV x 24 wks CP-B: 86% (12/14), w/rbv, 80% (12/15), w/o RBV, EU CUP, Welzel CP-C: 100% (2/2), w/rbv, 75% (6/8), w/o RBV, EU CUP, Welzel CP-B/C: 71% (12/17) w/o RBV, 70% (7/10) w/rbv, French Comp Access, 24 wks

Experienced Experienced GENOTYPE 4 Epclusa + RBV x 12 wks 100% (2/2; ASTRAL-4) Epclusa x 24 wks (if unable to take RBV) Harvoni x + RBV x 12 wks 93% (41/44, Study 1119, w/wo cirrhosis, no ribavirin). GENOTYPE 6 Harvoni x 24 wks (if unable to take RBV) 100% (2/2; ASTRAL-4) No data SOF + DCV + RBV x 24 wks CP-A/B/C: 100% (5/5), w/rbv, 100% (4/4), w/o RBV. EU CUP (SVR results did not break down by CP score) Epclusa + RBV x 12 wks No Data. Epclusa x 24 wks (if unable to take RBV) 100% (1/1; ASTRAL-4)

WITHOUT ribavirin PRE-HCV TREATMENT WORK UP Labs WITH ribavirin Required: HCV Genotype, HCV RNA, Liver/kidney panel, CBC, HIV, Hep A/B serologies and Baseline RAV testing (NS5A) to determine need for RBV and/or duration for: Genotype 3: naïve patients with cirrhosis and need to use Epclusa NS5A-experienced patients with cirrhosis where using Vosevi Genotype 1a: All patients if considering Zepatier Naïve patients with cirrhosis where you have to use Harvoni Consider: INR, HgbA1C, Lipid panel, vitamin A and D levels, cryoglobulins, UA, SPEP Labs Cardiac Eye exam Required: HCV Genotype, HCV RNA, Liver/kidney panel, CBC, HIV, uric Acid, Iron studies Hep A/B serologies and Baseline RAV testing (NS5A) to determine need for RBV and/or duration for: Genotype 3: naïve patients with cirrhosis and need to use Epclusa NS5A-experienced patients with cirrhosis where using Vosevi Genotype 1a: All patients if considering Zepatier Naïve patients with cirrhosis where you have to use Harvoni Consider: INR, HgbA1C, Lipid panel, vitamin A and D levels, cryoglobulins, UA, SPEP Consider Stress test based on risk factors and/or Framingham CHD risk score Not required, unless patient is Diabetic, has uncontrolled hypertension or has history of retinal problems Psychiatric If significant psych history, should have stable disease and be connected with psych providers prior to starting treatment Patients who relapse after DAA regimen: All: Repeat HCV Genotype to determine if patient had dual-strain infection or was reinfected NS5A or NS3/4A failure: 1. Order HCV Resistance testing if available for genotype (currently available for genotype 1 and 3). Recommend present DAA relapse cases at ECHO clinic.